New Drug Approvals

Home » Posts tagged 'ALCAFTADINE'

Tag Archives: ALCAFTADINE

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

Blog Stats

  • 4,238,516 hits

Flag and hits

Flag Counter

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,801 other subscribers
Follow New Drug Approvals on WordPress.com

Archives

Categories

Recent Posts

Flag Counter

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

SUBSCRIBE

New Drug Approvals

↑ Grab this Headline Animator

Subscribe in a reader

Enter your email address:

Delivered by FeedBurner

Subscribe to New Drug Approvals by Email

Add to Google Reader or Homepage

Subscribe in Bloglines

Add to The Free Dictionary

I heart FeedBurner

Subscribe in NewsGator Online

Add to netvibes

Add to Excite MIX

Add to fwicki

Add to Webwag

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,801 other subscribers
DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA, ROW2TECH, CLEANCHEM LABS as ADVISOR, earlier assignment was with GLENMARK LIFE SCIENCES LTD, as CONSUlTANT, Retired from GLENMARK in Jan2022 Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 32 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 PLUS year tenure till date Feb 2023, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 100 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 100 Lakh plus views on dozen plus blogs, 227 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 38 lakh plus views on New Drug Approvals Blog in 227 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc He has total of 32 International and Indian awards

Personal Links

Verified Services

View Full Profile →

Archives

Categories

Flag Counter

ALCAFTADINE, WO 2017211246, NEW PATENT, SHENZHEN TARGETRX, INC.

December 19, 2017 10:20 am / Leave a comment


Alcaftadine.svg

Alcaftadine

NEW PATENT

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017211246&redirectedID=true

WO-2017211246, SHENZHEN TARGETRX, INC.

SUBSTITUTED FUSED IMIDAZOLE CYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF

WANG, Yihan; (CN).
XING, Qingfeng; (CN)

Novel deuterated analogs of substituted fused imidazole cyclic compounds, particularly alcaftadine are histamine H1-receptor antagonists and mast cell stabilizers, useful for treating allergy and nasal congestion.

front page image

The present invention relates to a substituted fused imidazole cyclic compound and a composition containing said compound and application thereof. Specifically disclosed is the fused imidazole cyclic compound represented by formula (I), or a pharmaceutical composition of its crystalline form, pharmaceutically acceptable salt, prodrug, stereoisomer, hydrate, or solvate. The compound of the present invention may be used as a histamine H1-receptor antagonist and mast-cell stabilizer, and is capable of inhibiting mast-cell release of histamine and preventing histamine function, thereby reducing allergic reaction

str2

Example 1 Preparation of 6,11-dihydro -11- (1- (d3- methyl) piperidin-4-ylidene) -5H- imidazo [2,1-b] [3] benzazepine – 3- aldehyde (compound 8)

Step 1. Synthesis of compound 3.

N-benzyloxycarbonylpiperidine-4-carboxylic acid (2.63 g, 10 mmol) was dissolved in 20 mL of dichloromethane, 6 mL of oxalyl chloride and 1 drop of DMF were added and the mixture was reacted at room temperature for 2 hours under nitrogen. The reaction mixture was concentrated to dryness under reduced pressure, dissolved in 20 mL of acetonitrile, and added with triethylamine (4.1 mL, 30 mmol) in an ice bath and stirred for 3 minutes. A solution of 1-phenethyl-1H-imidazole (2.06 g, 12 mmol) in 5 mL of acetonitrile was slowly added dropwise and the reaction was allowed to warm to room temperature overnight after the addition was completed. The reaction was completed, concentrated to dryness, 30 mL of ethyl acetate and 20 mL of water were added and the mixture was stirred for 5 minutes. The layers were separated and the aqueous phase was extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate and concentrated to give 3.34 g of a colorless oil, benzyl-4- (1-phenethyl-1H-imidazole-2-formyl) piperidine-1-carboxylate (Compound 3) was obtained in a yield of 80%. ESI-MS: 418 [M ++ 1].

Step 2. Synthesis of compound 4.
Benzyl-4- (1-phenylethyl-1H-imidazole-2-formyl) piperidine-1-carboxylate (3.34 g, 8 mmol) was dissolved in 30 mL of absolute ethanol and 300 mg of 10% palladium on carbon , Hydrogen was substituted three times and stirred overnight at room temperature under a hydrogen atmosphere of 1 atmosphere. After completion of the reaction, the palladium carbon was filtered off and the filtrate was concentrated. 2.04 g of (1-phenethyl-1H-imidazol-2-yl) (piperidin-4-yl) methanone (Compound 4) 90%. ESI-MS: 284 [M ++ 1].
Step 3. Synthesis of compound 5.
(Piperidin-4-yl) methanone (2.04 g, 7.2 mmol) was dissolved in 10 mL of DMF and potassium carbonate (1.98 g, 14.4 mmol) The solution was cooled to -15 ° C and deuterated methyl iodide (1.02 g, 7.2 mmol) was slowly added dropwise under the protection of nitrogen. After the addition was completed, the mixture was stirred at room temperature for 0.5 hour. The mixture was extracted with ethyl acetate and extracted with ethyl acetate. The organic phase was washed once with 20 mL of water and 20 mL of saturated brine, dried over anhydrous sodium sulfate, concentrated and separated on a silica gel column (1- (methyl-d3) piperidine (1-phenethyl-1H-imidazol-2-yl) methanone (Compound 5) was obtained in an amount of 70%. 1 H NMR (300 MHz, CDCl 3 ) δ 7.23 (d, J = 2.0Hz, 1H), 7.06 (td, J = 4.2,3.8,1.7Hz, 3H), 6.86 (d, J = 1.0Hz, 1H) (Dd, J = 10.2, 5.8 Hz, 2H), 3.09 (t, J = 7.2 Hz, 2H) J = 7.2 Hz, 2H), 2.85-2.65 (m, 2H), 2.15 (td, J = 7.5, 3.9 Hz, 4H); ESI-MS: 301 [M ++ l ].
Step 4. Synthesis of Compound 6.
(1-phenethyl-1H-imidazol-2-yl) methanone (1.5 g, 5.1 mmol) was placed in a reaction flask and the mixture was purged with nitrogen three times , 7mL trifluoromethanesulfonic acid was added dropwise, the reaction was warmed to 110 ° C overnight. Cooled to room temperature, the reaction solution was poured into 30mL ice water, 50% sodium hydroxide solution was added dropwise to adjust the pH = 10-11, extracted with dichloromethane, the organic phase was washed once with 20mL of water and 20mL of saturated brine, Dried over sodium sulfate, concentrated and separated by silica gel column to obtain 0.85 g of compound 6, yield 60%. 1 H NMR (300 MHz, CDCl 3 ) δ 7.28 (d, J = 4.4 Hz, 2H), 7.23 (d, J = 5.0 Hz, 1H), 7.13 (d, J = 7.0 Hz, 1H), 7.02 (D, J = 1.3Hz, 1H), 4.38 (dt, J = 12.7, 3.9Hz, 1H), 4.02 (td, J = 13.3,3.1Hz, 1H), 3.59 -3.34 (m, 3H), 3.21 (s, 2H), 3.04-2.87 (m, 3H), 2.78-2.63 (m, 2H). ESI-MS: 283 [M ++ l ].
Step 5. Synthesis of compound 7.
Compound 6 (850 mg, 3 mmol) was placed in a reaction flask, followed by the addition of 0.5 mL of acetic acid, 5 mL of 37% formaldehyde and sodium acetate (87 mg, 1.1 mmol) and warming to 100 ° C overnight. After the reaction was cooled to room temperature completely, 30 mL of methylene chloride was added to the reaction solution, 50% sodium hydroxide solution was added dropwise to adjust pH = 11-12, stirred for 0.5 hour, and the layers were separated and the organic phase was washed with 10 mL of saturated saline , Dried over anhydrous sodium sulfate, concentrated and separated on a silica gel column to give the compound 7 340 mg, yield 36%. ESI-MS: 313 [M ++ 1].
Step 6. Synthesis of Compound 8.
Compound 7 (340 mg, 1.1 mmol) was dissolved in 20 mL of dichloromethane and 4-dimethylaminopyridine (DMAP, 13 mg, 0.11 mmol) and Dess-Martin Periodinane 1.3 mmol) and reacted at room temperature for 3 hours. Join 20mL saturated sodium bicarbonate solution and 20mL dichloromethane, stirred for 5 minutes, filtered and the filtrate was separated. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated. The compound 8 270mg was obtained by silica gel column, and the yield was 80%. 1 H NMR (300 MHz, CDCl 3 ) δ 9.64 (s, 1H), 7.76 (s, 1H), 7.34-7.26 (m, 3H), 7.16 (d, J = 6.7 Hz, 1H), 4.74 J = 14.5, 3.9 Hz, 1H), 4.31 (td, J = 14.1, 3.2 Hz, 1H), 3.53 (td, 3.03-2.89 (m, 4H), 2.64-2.81 (m, 4H); ESI-MS: 311 [M ++ l ].

//////////////

LASTACAFT, ALCAFTADINE.. Drug Patent Expiration, 21st Nov 2013

October 25, 2013 4:01 am / 1 Comment on LASTACAFT, ALCAFTADINE.. Drug Patent Expiration, 21st Nov 2013


ALCAFTADINE

Alcaftadine is used to prevent eye irritation brought on by allergic conjunctivitis. It is a H1histamine receptor antagonist.

It was approved by the U.S. Food and Drug Administration in 2010 under the trade name Lastacaft.

LASTACAFT, ALLERGAN

Drug Patent Expiration and Exclusivity

Active Ingredient Form Dosage Drug Type Application Product
ALCAFTADINE SOLUTION/DROPS; OPHTHALMIC 0.25% RX 022134 001

Patents

There are 1 patent(s) protecting ALLERGAN’s LASTACAFT.
The last patent expires on 2013-11-21.

Patent Expiration
US5468743 Imidazo[2,1-b]benzazepine derivatives, compositions and method of use

The present invention is concerned with novel imidazo[2, 1-b][3]benzazepines of formula ##STR1## the pharmaceutically acceptable addition salts and stereochemically isomeric forms thereof, wherein each of the dotted lines independently represents an optional bond; R.sup.1 represents hydrogen, halo, C.sub.1-4 alkyl or C.sub.1-4 alkyloxy; R.sup.2 represents hydrogen, halo, C.sub.1-4 alkyl or C.sub.1-4 alkyloxy; R.sup.3 represents hydrogen, C.sub.1-4 alkyl, ethenyl substituted with hydroxycarbonyl or C.sub.1-4 alkyloxycarbonyl, C.sub.1-4 alkyl substituted with hydroxycarbonyl or C.sub.1-4 alkyloxycarbonyl, hydroxyC.sub.1-4 alkyl, formyl or hydroxycarbonyl; R.sup.4 represents hydrogen, C.sub.1-4 alkyl, hydroxyC.sub.1-4 alkyl, phenyl or halo; R.sup.5 represents hydrogen, C.sub.1-4 alkyl or halo; L represents hydrogen; C.sub.1-6 alkyl; C.sub.1-6 alkyl substituted with one substituent selected from the group consisting of hydroxy, halo, C.sub.1-4 alkyloxy, hydroxycarbonyl, C.sub.1-4 alkyloxycarbonyl, C.sub.1-4 alkyloxycarbonyl-C.sub.1-4 alkyloxy, hydroxycarbonylC.sub.1-4 alkyloxy, C.sub.1-4 alkyloxycarbonylamino, C.sub.1-4 alkylaminocarbonyl, C.sub.1-4 alkylaminocarbonylamino, C.sub.1-4 alkylaminothiocarbonylamino, aryl, aryloxy and arylcarbonyl; C.sub.1-6 alkyl substituted with both hydroxy and aryloxy; C.sub.3-6 alkenyl; C.sub.3-6 alkenyl substituted with aryl; or, L represents a radical of formula –Alk–Y–Het.sup.1 (a-1),–Alk–NH–CO–Het.sup.2 (a-2)or –Alk–Het.sup.3 (a-3); provided that 6,11-dihydro-11-(4-piperidinylidene)-5H-imidazo[2,1-b][3]benzazepine is ecxluded, which are useful antiallergic compounds.Compositions comprising said compounds, methods of using and processes for preparing the same.
 2013-11-21

Exclusivity

Exclusivity is marketing rights granted by the FDA to the ALLERGAN.
Exclusivity ends on 2015-07-28.

Approval History
Date Supplement No. Action Documents
2010-07-28 000 Approval
%d bloggers like this: